Needham & Company
-
Companies with NDRs 3/24
-
Companies with NDRs 11/21
-
Akebia Therapeutics to Present at the 18th Annual Needham Healthcare Conference
-
Akebia Therapeutics (AKBA) PT Lowered to $18 at Needham & Company
-
Akebia Therapeutics to Present at Upcoming Investor Conferences
-
Akebia Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters
-
Akebia Therapeutics (AKBA) Prices 4M Share Offering at $14.50/Sh
-
Akebia Announces Pricing of Public Offering of Common Stock
-
Akebia Therapeutics (AKBA) PT Raised to $21 at Needham & Company
-
Akebia Therapeutics (AKBA) PT Raised to $18 at Needham & Company
-
Akebia to Present at the 16th Annual Needham Healthcare Conference
-
Otsuka Partnership Removes Akebia Therapeutics (AKBA) Financial Overhang - Needham & Company
-
Akebia to Present at the 15th Annual Needham Healthcare Conference
-
Akebia Therapeutics (AKBA) Prices 7.25M Shares at $9
-
Akebia Prices Public Offering of Common Stock
-
Akebia Therapeutics (AKBA) Announces $75M Common Stock Offering
-
Akebia Therapeutics Announces Proposed Public Offering of Common Stock
-
Akebia (AKBA) PT Raised to $18 at Needham & Company
-
Needham & Company Reiterates Buy on Akebia Therapeutics (AKBA) Following Successful Meetings with FDA and EMA
-
Needham & Company Starts Akebia Therapeutics (AKBA) at Buy
-
Akebia Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Akebia Therapeutics (AKBA) Prices 7.27M Common Offering at $8.25/Share
-
Akebia Therapeutics Prices Public Offering of Common Stock
-
Akebia Therapeutics (AKBA) Announces $60M Common Offering
-
Akebia Therapeutics Announces Proposed Public Offering of Common Stock

